Webinar preview: Most Favored Nation mandate takes center stage in drug pricing debate

The stakes are rising in Washington’s drug pricing debate, and the Most Favored Nation (MFN) initiative is at the center of it all. On September 10, MJH Life Sciences^® will host the first installment of a three-part webinar series, “The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients,” beginning with a roundtable discussion examining what the mandate means across the health care landscape.

Click here to register.

Inside the MFN debate

The MFN initiative represents one of the most consequential — and contentious — drug pricing policies in recent memory. The series will explore how the program could alter pricing strategies, disrupt payer and pharmacy benefit manager (PBM) contracts and reshape patient access to therapies.

The roundtable discussions will cover:

• The state of play: who stands to benefit, who could lose and what comes next.
• Pharma’s legal challenges and pricing strategies.
• Consequences for research and development, global competition and U.S. first-to-launch status.
• Payer and market disruptions in rebate structures and distribution models.
• The patient perspective: affordability and access under MFN.

Attendees will learn how MFN could reshape U.S. and global pricing strategies over the next three to five years, identify the biggest legal and commercial risks and anticipate the potential impacts on affordability and innovation.

This webinar brings together leaders from across the health care industry for candid debate, bold perspectives and actionable insights.

For anyone with a stake in the business, policy or delivery of health care, the discussions will provide a critical guide to navigating uncertainty in the drug pricing landscape.

Meet the panelists

The discussion will be moderated by Ned Milenkovich, Pharm.D., J.D., an attorney and registered pharmacist who chairs the health care law practice at Much Shelist, P.C. and is the former vice chairman of the Illinois State Board of Pharmacy. He is also a longtime thought leader, serving on the Pharmacy Times editorial advisory board and regularly speaking at industry events.

The panel will feature Brian Corvino, principal and global market access practice leader at Deloitte US, who has more than two decades of expertise in life sciences commercial and market access strategy, including sustainable affordability and launch planning across traditional, specialty, oncology, cell and gene therapy and rare disease treatments.

Joining him is Neal Masia, Ph.D., co-founder and CEO of EntityRisk, Inc., founder of Health Capital Group, LLC, and adjunct professor of management and economics at Columbia University. Masia’s background includes nearly two decades in senior leadership roles at Pfizer, spanning health economics, strategic business development and market access.

Ali Pashazadeh, founder, chairman and CEO of Treehill Partners, will also join the conversation. He brings more than 20 years of experience as a health care investment banker at Goldman Sachs, UBS and Blackstone, as well as his perspective as a biotech CEO and trained trauma and reconstructive surgeon still practicing in acute care.

Rounding out the panel is George Van Antwerp, MBA, senior vice president of product innovation and strategic planning at Prime Therapeutics, where he oversees teams developing, launching and managing pharmacy offerings. He previously worked at Deloitte, where he led the health care practice with a focus on pharmacy.

Click here to register.

The webinar series is produced in collaboration with MJH Life Sciences’ leading health care brands, including The American Journal of Managed Care^®, Chief Healthcare Executive^®, Drug Topics^®, HCPLive®, Managed Healthcare Executive^®, Medical Economics^®, OncLive^®, Pharmaceutical Commerce^®, Pharmaceutical Executive^® and Pharmacy Times^®.